203 Publications (Page 1 of 9)
2023
APE1/Ref-1 as a Therapeutic Target for Inflammatory Bowel Disease
Sahakian, Lauren⋅Robinson, Ainsley M⋅Sahakian, Linda⋅Stavely, Rhian⋅Kelley, Mark R⋅Nurgali, Kulmira and Nurgali, Kulmira
Biomolecules, vol. 13, (no. 11), 2023. | Journal Article
2021
Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours
Zhang, Chi⋅Zhang, Chi⋅Zhang, Chi⋅Zhang, Chi⋅Rhodes, Steven D⋅Rhodes, Steven D⋅Rhodes, Steven D⋅Rhodes, Steven D⋅Babb, Olivia⋅Babb, Olivia⋅Babb, Olivia⋅Babb, Olivia⋅Grimard, Michelle⋅Grimard, Michelle⋅Grimard, Michelle⋅Grimard, Michelle⋅Calver, Brian⋅Calver, Brian⋅Calver, Brian⋅Calver, Brian⋅Ren-Yuan, Bai⋅Ren-Yuan, Bai⋅Ren-Yuan, Bai⋅Ren-Yuan, Bai⋅Hulsey, Emily L⋅Hulsey, Emily L⋅Hulsey, Emily L⋅Hulsey, Emily L⋅Reza, Saadatzadeh M⋅Reza, Saadatzadeh M⋅Reza, Saadatzadeh M⋅Reza, Saadatzadeh M⋅Pollok, Karen E⋅Pollok, Karen E⋅Pollok, Karen E⋅Pollok, Karen E⋅Tong, Yan⋅Tong, Yan⋅Tong, Yan⋅Tong, Yan⋅Smith, Abbi E⋅Smith, Abbi E⋅Smith, Abbi E⋅Smith, Abbi E⋅Wade, Clapp D⋅Wade, Clapp D⋅Wade, Clapp D⋅Wade, Clapp D⋅Tee, Andrew R⋅Tee, Andrew R⋅Tee, Andrew R⋅Tee, Andrew R⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Fishel, Melissa L⋅Fishel, Melissa L⋅Fishel, Melissa L and Fishel, Melissa L
The British Journal of Cancer, vol. 124, (no. 9), pp. 1566-1580, Apr 2021. | Journal Article
 
Inhibition of APE1/Ref-1 for Neovascular Eye Diseases: From Biology to Therapy
Hartman, Gabriella D⋅Lambert-Cheatham, Nathan A⋅Kelley, Mark R⋅Corson, Timothy W and Corson, Timothy W
International Journal of Molecular Sciences, vol. 22, (no. 19), 2021. | Journal Article
 
Ref-1 redox activity alters cancer cell metabolism in pancreatic cancer: exploiting this novel finding as a potential target
Gampala, Silpa⋅Gampala, Silpa⋅Gampala, Silpa⋅Shah, Fenil⋅Shah, Fenil⋅Shah, Fenil⋅Lu, Xiaoyu⋅Lu, Xiaoyu⋅Lu, Xiaoyu⋅Moon, Hye-Ran⋅Moon, Hye-Ran⋅Moon, Hye-ran⋅Babb, Olivia⋅Babb, Olivia⋅Babb, Olivia⋅Ganesh, Nikkitha Umesh⋅Nikkitha, Umesh G⋅Ganesh, Nikkitha Umesh⋅Sandusky, George⋅Sandusky, George⋅Sandusky, George⋅Hulsey, Emily⋅Hulsey, Emily⋅Hulsey, Emily⋅Armstrong, Lee⋅Armstrong, Lee⋅Armstrong, Lee⋅Mosely, Amber L⋅Mosely, Amber L⋅Mosely, Amber L⋅Han, Bumsoo⋅Han, Bumsoo⋅Han, Bumsoo⋅Ivan, Mircea⋅Ivan, Mircea⋅Yeh, Jing-Ruey Joanna⋅Yeh, Jing-Ruey Joanna⋅Jing-Ruey, Joanna Y⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Zhang, Chi⋅Zhang, Chi⋅Zhang, Chi⋅Fishel, Melissa L⋅Fishel, Melissa L and Fishel, Melissa L
Journal of Experimental and Clinical Cancer Research, vol. 40, pp. 1-24, 2021. | Journal Article
2019
Anti-tumor activity and mechanistic characterization of APE1/Ref-1 inhibitors in bladder cancer
Fishel, Melissa L⋅Fishel, Melissa L⋅Fishel, Melissa L⋅Fishel, Melissa L⋅Fishel, Melissa L⋅Fishel, Melissa L⋅Fishel, Melissa L⋅Fishel, Melissa L⋅Xia, Hanyu⋅Xia, Hanyu⋅Xia, Hanyu⋅Xia, Hanyu⋅Xia, Hanyu⋅Xia, Hanyu⋅Xia, Hanyu⋅Xia, Hanyu⋅McGeown, Jack⋅McGeown, Jack⋅McGeown, Jack⋅McGeown, Jack⋅McGeown, Jack⋅McGeown, Jack⋅McGeown, Jack⋅McGeown, Jack⋅McIlwain, David W⋅McIlwain, David W⋅McIlwain, David W⋅McIlwain, David W⋅McIlwain, David W⋅McIlwain, David W⋅McIlwain, David W⋅McIlwain, David W⋅Elbanna, May⋅Elbanna, May⋅Elbanna, May⋅Elbanna, May⋅Elbanna, May⋅Elbanna, May⋅Elbanna, May⋅Elbanna, May⋅Craft, Ariel A⋅Craft, Ariel A⋅Craft, Ariel A⋅Craft, Ariel A⋅Craft, Ariel A⋅Craft, Ariel A⋅Craft, Ariel A⋅Craft, Ariel A⋅Kaimakliotis, Hristos Z⋅Kaimakliotis, Hristos Z⋅Kaimakliotis, Hristos Z⋅Kaimakliotis, Hristos Z⋅Kaimakliotis, Hristos Z⋅Kaimakliotis, Hristos Z⋅Kaimakliotis, Hristos Z⋅Kaimakliotis, Hristos Z⋅Sandusky, George E⋅Sandusky, George E⋅Sandusky, George E⋅Sandusky, George E⋅Sandusky, George E⋅Sandusky, George E⋅Sandusky, George E⋅Sandusky, George E⋅Zhang, Chi⋅Zhang, Chi⋅Zhang, Chi⋅Zhang, Chi⋅Zhang, Chi⋅Zhang, Chi⋅Zhang, Chi⋅Zhang, Chi⋅Pili, Roberto⋅Pili, Roberto⋅Pili, Roberto⋅Pili, Roberto⋅Pili, Roberto⋅Pili, Roberto⋅Pili, Roberto⋅Pili, Roberto⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Jerde, Travis J⋅Jerde, Travis J⋅Jerde, Travis J⋅Jerde, Travis J⋅Jerde, Travis J⋅Jerde, Travis J⋅Jerde, Travis J and Jerde, Travis J
Molecular cancer therapeutics, vol. 18, (no. 11), pp. 1960, 20191100. | Journal Article
 
A phase I study of the APE1 protein inhibitor APX3330 in patients with advanced solid tumors
Shahda, Safi⋅Shahda, Safi⋅Shahda, Safi⋅Lakhani, Nehal J⋅Lakhani, Nehal J⋅Lakhani, Nehal J⋅O'Neil, Bert⋅O'Neil, Bert⋅O'Neil, Bert⋅Rasco, Drew W⋅Rasco, Drew W⋅Rasco, Drew W⋅Wan, Jun⋅Wan, Jun⋅Wan, Jun⋅Mosley, Amber L⋅Mosley, Amber L⋅Mosley, Amber L⋅Liu, Hao⋅Liu, Hao⋅Liu, Hao⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Messmann, Richard Adam⋅Messmann, Richard Adam and Messmann, Richard Adam
Journal of Clinical Oncology, vol. 37, (no. 15_suppl), pp. 3097, 2019-05-20. | Journal Article
 
CTC enumeration and characterization as a pharmacodynamic marker in the phase I clinical study of APX3330, an APE1/Ref-1 inhibitor, in patients with advanced solid tumors
Chu, Lincy⋅Anderson, Amanda K. L⋅Landers, Mark Andrew⋅Wang, Yipeng⋅Kelley, Mark R and Messmann, Richard Adam
Journal of Clinical Oncology, vol. 37, (no. 15_suppl), pp. e14531, 2019-05-20. | Journal Article
 
Discovery of Macrocyclic Inhibitors of Apurinic/Apyrimidinic Endonuclease 1
Trilles, Richard⋅Trilles, Richard⋅Beglov, Dmitri⋅Beglov, Dmitri⋅Chen, Qiujia⋅Chen, Qiujia⋅He, Hongzhen⋅He, Hongzhen⋅Wireman, Randall⋅Wireman, Randall⋅Reed, April⋅Reed, April⋅Chennamadhavuni, Spandan⋅Chennamadhavuni, Spandan⋅Panek, James S⋅Panek, James S⋅Brown, Lauren E⋅Brown, Lauren E⋅Vajda, Sandor⋅Vajda, Sandor⋅Porco, Jr, John A⋅Porco, Jr, John A⋅Kelley, Mark R⋅Kelley, Mark R⋅Georgiadis, Millie M and Georgiadis, Millie M
Journal of medicinal chemistry, vol. 62, (no. 4), pp. 1988, 2019-02-28. | Journal Article
 
Endonuclease and redox activities of human apurinic/apyrimidinic endonuclease 1 have distinctive and essential functions in IgA class switch recombination
Frossi, Barbara⋅Frossi, Barbara⋅Frossi, Barbara⋅Frossi, Barbara⋅Frossi, Barbara⋅Antoniali, Giulia⋅Antoniali, Giulia⋅Antoniali, Giulia⋅Antoniali, Giulia⋅Antoniali, Giulia⋅Yu, Kefei⋅Yu, Kefei⋅Yu, Kefei⋅Yu, Kefei⋅Yu, Kefei⋅Akhtar, Nahid⋅Akhtar, Nahid⋅Akhtar, Nahid⋅Akhtar, Nahid⋅Akhtar, Nahid⋅Kaplan, Mark H⋅Kaplan, Mark H⋅Kaplan, Mark H⋅Kaplan, Mark H⋅Kaplan, Mark H⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Tell, Gianluca⋅Tell, Gianluca⋅Tell, Gianluca⋅Tell, Gianluca⋅Tell, Gianluca⋅Pucillo, Carlo E M⋅Pucillo, Carlo E M⋅Pucillo, Carlo E M⋅Pucillo, Carlo E M and Pucillo, Carlo E M
The Journal of biological chemistry, vol. 294, (no. 13), pp. 5207, 2019-03-29. | Journal Article
 
Inhibition of APE1-endonuclease activity affects cell metabolism in colon cancer cells via a p53-dependent pathway
Codrich, Marta⋅Comelli, Marina⋅Malfatti, Matilde Clarissa⋅Mio, Catia⋅Ayyildiz, Dilara⋅Zhang, Chi⋅Kelley, Mark R⋅Terrosu, Giovanni⋅Pucillo, Carlo E.M and Tell, Gianluca
DNA Repair, vol. 82, pp. 102675, October 2019. | Journal Article
2018
Abstract 2941: APE1/Ref-1 redox signaling regulates HIF1a-mediated CA9 expression in hypoxic pancreatic cancer cells: Combination treatment in patient-derived pancreatic tumor models
Logsdon, Derek⋅Logsdon, Derek⋅Shah, Fenil⋅Shah, Fenil⋅Carta, Fabrizio⋅Carta, Fabrizio⋅Supuran, Claudiu⋅Supuran, Claudiu⋅Fishel, Melissa⋅Fishel, Melissa⋅Kelley, Mark R and Kelley, Mark R
Cancer Research, vol. 78, (no. 13 Supplement), pp. 2941, 2018-07-01. | Journal Article
 
Abstract 4802: Combination therapy in PDAC involving blockade of the APE1/Ref-1 signaling pathway: An investigation into drug synthetic lethality and anti-neuropathy therapeutic approach
Shah, Fenil L⋅Shah, Fenil L⋅Shah, Fenil L⋅Atallah, Nadia⋅Atallah, Nadia⋅Atallah, Nadia⋅Grimard, Michelle⋅Grimard, Michelle⋅Grimard, Michelle⋅Guo, Chunlu⋅Guo, Chunlu⋅Guo, Chunlu⋅Zhang, Chi⋅Zhang, Chi⋅Zhang, Chi⋅Fehrenbacher, Jill⋅Fehrenbacher, Jill⋅Fehrenbacher, Jill⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Fishel, Melissa⋅Fishel, Melissa and Fishel, Melissa
Cancer Research, vol. 78, (no. 13 Supplement), pp. 4802, 2018-07-01. | Journal Article
 
APE1/Ref-1 redox-specific inhibition decreases survivin protein levels and induces cell cycle arrest in prostate cancer cells
McIlwain, David W⋅McIlwain, David W⋅McIlwain, David W⋅Fishel, Melissa L⋅Fishel, Melissa L⋅Fishel, Melissa L⋅Boos, Alexander⋅Boos, Alexander⋅Boos, Alexander⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Jerde, Travis J⋅Jerde, Travis J and Jerde, Travis J
Oncotarget, vol. 9, (no. 13), pp. 10977, 2018-Feb-16. | Journal Article
 
APX3330 Promotes Neurorestorative Effects after Stroke in Type One Diabetic Rats.
Yan, Tao⋅Venkat, Poornima⋅Chopp, Michael⋅Zacharek, Alex⋅Yu, Peng⋅Ning, Ruizhuo⋅Qiao, Xiaoxi⋅Kelley, Mark R and Chen, Jieli
Aging and disease, vol. 9, (no. 3), pp. 453-466, June 2018. | Journal Article
 
Blocking HIF signaling via novel inhibitors of CA9 and APE1/Ref-1 dramatically affects pancreatic cancer cell survival.
Logsdon, Derek P⋅Logsdon, Derek P⋅Logsdon, Derek P⋅Logsdon, Derek P⋅Shah, Fenil⋅Shah, Fenil⋅Shah, Fenil⋅Shah, Fenil⋅Carta, Fabrizio⋅Carta, Fabrizio⋅Carta, Fabrizio⋅Carta, Fabrizio⋅Supuran, Claudiu T⋅Supuran, Claudiu T⋅Supuran, Claudiu T⋅Supuran, Claudiu T⋅Kamocka, Malgorzata⋅Kamocka, Malgorzata⋅Kamocka, Malgorzata⋅Kamocka, Malgorzata⋅Jacobsen, Max H⋅Jacobsen, Max H⋅Jacobsen, Max H⋅Jacobsen, Max H⋅Sandusky, George E⋅Sandusky, George E⋅Sandusky, George E⋅Sandusky, George E⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Fishel, Melissa L⋅Fishel, Melissa L⋅Fishel, Melissa L and Fishel, Melissa L
Scientific reports, vol. 8, (no. 1), pp. 13759, September 13, 2018. | Journal Article
 
Downregulation of Morrbid in Tet2-Deficient Preleukemic Cells Overcomes Resistance to Inflammatory Stress and Mitigates Clonal Hematopoiesis
Cai, Zhigang⋅Cai, Zhigang⋅Cai, Zhigang⋅Cai, Zhigang⋅Cai, Zhigang⋅Kotzin, Jonathan⋅Kotzin, Jonathan⋅Kotzin, Jonathan⋅Kotzin, Jonathan⋅Kotzin, Jonathan⋅Ramdas, Baskar⋅Ramdas, Baskar⋅Ramdas, Baskar⋅Ramdas, Baskar⋅Ramdas, Baskar⋅Chen, Sisi⋅Chen, Sisi⋅Chen, Sisi⋅Chen, Sisi⋅Chen, Sisi⋅Nelanuthala, Sai⋅Nelanuthala, Sai⋅Nelanuthala, Sai⋅Nelanuthala, Sai⋅Nelanuthala, Sai⋅Palam, Lakshmi Reddy⋅Palam, Lakshmi Reddy⋅Palam, Lakshmi Reddy⋅Palam, Lakshmi Reddy⋅Palam, Lakshmi Reddy⋅Pandey, Ruchi⋅Pandey, Ruchi⋅Pandey, Ruchi⋅Pandey, Ruchi⋅Pandey, Ruchi⋅Mali, Raghuveer⋅Mali, Raghuveer⋅Mali, Raghuveer⋅Mali, Raghuveer⋅Mali, Raghuveer⋅Liu, Yan⋅Liu, Yan⋅Liu, Yan⋅Liu, Yan⋅Liu, Yan⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Sandusky, George⋅Sandusky, George⋅Sandusky, George⋅Sandusky, George⋅Sandusky, George⋅Mohseni, Morvarid⋅Mohseni, Morvarid⋅Mohseni, Morvarid⋅Mohseni, Morvarid⋅Mohseni, Morvarid⋅Williams, Adam⋅Williams, Adam⋅Williams, Adam⋅Williams, Adam⋅Williams, Adam⋅Henao-Mejia, Jorge⋅Henao-Mejia, Jorge⋅Henao-Mejia, Jorge⋅Henao-Mejia, Jorge⋅Henao-Mejia, Jorge⋅Kapur, Reuben⋅Kapur, Reuben⋅Kapur, Reuben⋅Kapur, Reuben and Kapur, Reuben
Blood, vol. 132, (no. Supplement 1), pp. 1288, 2018-11-29. | Journal Article
 
Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis.
Cai, Zhigang⋅Cai, Zhigang⋅Cai, Zhigang⋅Cai, Zhigang⋅Cai, Zhigang⋅Cai, Zhigang⋅Cai, Zhigang⋅Kotzin, Jonathan J⋅Kotzin, Jonathan J⋅Kotzin, Jonathan J⋅Kotzin, Jonathan J⋅Kotzin, Jonathan J⋅Kotzin, Jonathan J⋅Kotzin, Jonathan J⋅Ramdas, Baskar⋅Ramdas, Baskar⋅Ramdas, Baskar⋅Ramdas, Baskar⋅Ramdas, Baskar⋅Ramdas, Baskar⋅Ramdas, Baskar⋅Chen, Sisi⋅Chen, Sisi⋅Chen, Sisi⋅Chen, Sisi⋅Chen, Sisi⋅Chen, Sisi⋅Chen, Sisi⋅Nelanuthala, Sai⋅Nelanuthala, Sai⋅Nelanuthala, Sai⋅Nelanuthala, Sai⋅Nelanuthala, Sai⋅Nelanuthala, Sai⋅Nelanuthala, Sai⋅Palam, Lakshmi Reddy⋅Palam, Lakshmi Reddy⋅Palam, Lakshmi Reddy⋅Palam, Lakshmi Reddy⋅Palam, Lakshmi Reddy⋅Palam, Lakshmi Reddy⋅Palam, Lakshmi Reddy⋅Pandey, Ruchi⋅Pandey, Ruchi⋅Pandey, Ruchi⋅Pandey, Ruchi⋅Pandey, Ruchi⋅Pandey, Ruchi⋅Pandey, Ruchi⋅Mali, Raghuveer Singh⋅Mali, Raghuveer Singh⋅Mali, Raghuveer Singh⋅Mali, Raghuveer Singh⋅Mali, Raghuveer Singh⋅Mali, Raghuveer Singh⋅Mali, Raghuveer Singh⋅Liu, Yan⋅Liu, Yan⋅Liu, Yan⋅Liu, Yan⋅Liu, Yan⋅Liu, Yan⋅Liu, Yan⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R⋅Sandusky, George⋅Sandusky, George⋅Sandusky, George⋅Sandusky, George⋅Sandusky, George⋅Sandusky, George⋅Sandusky, George⋅Mohseni, Morvarid⋅Mohseni, Morvarid⋅Mohseni, Morvarid⋅Mohseni, Morvarid⋅Mohseni, Morvarid⋅Mohseni, Morvarid⋅Mohseni, Morvarid⋅Williams, Adam⋅Williams, Adam⋅Williams, Adam⋅Williams, Adam⋅Williams, Adam⋅Williams, Adam⋅Williams, Adam⋅Henao-Mejia, Jorge⋅Henao-Mejia, Jorge⋅Henao-Mejia, Jorge⋅Henao-Mejia, Jorge⋅Henao-Mejia, Jorge⋅Henao-Mejia, Jorge⋅Henao-Mejia, Jorge⋅Kapur, Reuben⋅Kapur, Reuben⋅Kapur, Reuben⋅Kapur, Reuben⋅Kapur, Reuben⋅Kapur, Reuben and Kapur, Reuben
Cell stem cell, vol. 23, (no. 6), pp. 833-849.e5, December 6, 2018. | Journal Article
 
Novel first-in-class small molecule targeting APE1/Ref-1 to prevent and treat chemotherapy-induced peripheral neuropathy (CIPN)
Kelley, Mark R⋅Kelley, Mark R⋅Messmann, Richard Adam⋅Messmann, Richard Adam⋅Fehrenbacher, Jill and Fehrenbacher, Jill
Journal of Clinical Oncology, vol. 36, (no. 34_suppl), pp. 229, 2018-12-01. | Journal Article
 
Ref-1/APE1 inhibition with novel small molecules blocks ocular neovascularization.
Sardar Pasha, Sheik Pran Babu⋅Sardar Pasha, Sheik Pran Babu⋅Sishtla, Kamakshi⋅Sishtla, Kamakshi⋅Sulaiman, Rania S⋅Sulaiman, Rania S⋅Park, Bomina⋅Park, Bomina⋅Shetty, Trupti⋅Shetty, Trupti⋅Shah, Fenil⋅Shah, Fenil⋅Fishel, Melissa L⋅Fishel, Melissa L⋅Wikel, James H⋅Wikel, James H⋅Kelley, Mark R⋅Kelley, Mark R⋅Corson, Timothy W and Corson, Timothy W
The Journal of pharmacology and experimental therapeutics, August 3, 2018. | Journal Article
2017
APE1/Ref‐1 knockdown in pancreatic ductal adenocarcinoma – characterizing gene expression changes and identifying novel pathways using single‐cell RNA sequencing
Shah, Fenil⋅Shah, Fenil⋅Shah, Fenil⋅Goossens, Emery⋅Goossens, Emery⋅Goossens, Emery⋅Atallah, Nadia M.⋅Atallah, Nadia M⋅Atallah, Nadia M⋅Grimard, Michelle⋅Grimard, Michelle⋅Grimard, Michelle⋅Kelley, Mark R⋅Kelley, Mark R⋅Kelley, Mark R.⋅Fishel, Melissa L.⋅Fishel, Melissa L and Fishel, Melissa L
Molecular Oncology, vol. 11, (no. 12), pp. 1732, December 2017. | Journal Article
 
Challenges and opportunities identifying therapeutic targets for chemotherapy-induced peripheral neuropathy resulting from oxidative DNA damage.
Kelley, Mark R and Fehrenbacher, Jill C
Neural regeneration research, vol. 12, (no. 1), pp. 72-74, January 2017. | Journal Article
 
Current Molecular Pharmacology: Meet Our Editorial Board Member
Kelley, Mark
Current Molecular Pharmacology, vol. 10, (no. 4), pp. 256, 2017-November. | Journal Article
 
DNA damage mediates changes in neuronal sensitivity induced by the inflammatory mediators, MCP-1 and LPS, and can be reversed by enhancing the DNA repair function of APE1
Fehrenbacher, Jill C⋅Fehrenbacher, Jill C⋅Guo, Chunlu⋅Guo, Chunlu⋅Kelley, Mark R⋅Kelley, Mark R⋅Vasko, Michael R and Vasko, Michael R
Neuroscience, vol. 366, pp. 35, 2017-12-16. | Journal Article
 
Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic.
Shah, Fenil⋅Shah, Fenil⋅Logsdon, Derek⋅Logsdon, Derek⋅Messmann, Richard A⋅Messmann, Richard A⋅Fehrenbacher, Jill C⋅Fehrenbacher, Jill C⋅Fishel, Melissa L⋅Fishel, Melissa L⋅Kelley, Mark R and Kelley, Mark R
NPJ precision oncology, vol. 1, 2017. | Journal Article
 
Meet Our Editorial Board Member
Saykin, Andrew J and Kelley, Mark R
Current Molecular Pharmacology, vol. 10, (no. 4), 2017-10-04. | Journal Article